Literature DB >> 6246496

Specificity of human antibodies to oncovirus glycoproteins: recognition of antigen by natural antibodies directed against carbohydrate structures.

H W Snyder, E Fleissner.   

Abstract

Antibodies in human sera from healthy individuals were shown to be reactive with highly purified 70,000-dalton envelope glycoprotein (gp70) of the simian sarcoma virus-simian sarcoma-associated virus (SSV-SSAV) complex in radioimmunoprecipitation assays under certain conditions. The specificity of the reaction was analyzed in absorption tests with normal human serum proteins, assays of viral gp70 antigenicity after exposure to exo- and endoglycosidases or trypsin, and carbohydrate hapten inhibition studies. On the basis of the results obtained in these experiments we have concluded that immune recognition of SSV-SSAV gp70 can be mediated by naturally occurring heterophil antibodies in human sera that are reactive by virtue of binding to the carbohydrate moiety of the viral gp70 molecules. The results are consistent with the idea that the antibodies in question are elicited as a result of exposure to many natural substances possessing widely crossreacting antigens and are not a result of widespread infection of man with replication-competent oncoviruses.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6246496      PMCID: PMC348549          DOI: 10.1073/pnas.77.3.1622

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Mosquito cells infected with vesicular stomatitis virus yield unsialylated virions of low infectivity.

Authors:  R H Schloemer; R R Wagner
Journal:  J Virol       Date:  1975-04       Impact factor: 5.103

2.  Seroepidemiology of human sarcoma antigen (S1).

Authors:  Y Hirshaut; D T Pei; R C Marcove; B Mukherji; A R Spielvogel; E Essner
Journal:  N Engl J Med       Date:  1974-11-21       Impact factor: 91.245

3.  A survey of cats and humans for prevalence of feline leukemia-sarcoma virus neutralizing serum antibodies.

Authors:  P S Sarma; A Sharar; V Walters; M Gardner
Journal:  Proc Soc Exp Biol Med       Date:  1974-02

4.  Failure to detect, in human sera, antibodies cross-reactive with group-specific antigens of murine leukemia virus.

Authors:  H P Charman; N Kim; M White; R V Gilden
Journal:  J Natl Cancer Inst       Date:  1974-05       Impact factor: 13.506

5.  Immunodiffusion studies of feline leukemia and sarcoma.

Authors:  W D Hardy
Journal:  J Am Vet Med Assoc       Date:  1971-03-15       Impact factor: 1.936

6.  Carbohydrate inhibition studies of the naturally occurring human antibody to neuraminidase-treated human lymphocytes.

Authors:  G N Rogentine; B A Plocinik
Journal:  J Immunol       Date:  1974-09       Impact factor: 5.422

7.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

8.  Sindbis virus glycoproteins: effect of the host cell on the oligosaccharides.

Authors:  K Keegstra; B Sefton; D Burke
Journal:  J Virol       Date:  1975-09       Impact factor: 5.103

9.  Antigenic determinants of the 70,000 molecular weight glycoprotein of woolly monkey type C RNA virus.

Authors:  S Hino; J R Stephenson; S A Aaronson
Journal:  J Immunol       Date:  1975-10       Impact factor: 5.422

10.  Properties of mouse leukemia viruses. VII. The major viral glycoprotein of friend leukemia virus. Isolation and physicochemical properties.

Authors:  V Moennig; H Frank; G Hunsmann; I Schneider; W Schafer
Journal:  Virology       Date:  1974-09       Impact factor: 3.616

View more
  19 in total

1.  Comments on the paper by M.T.Zenzes and T.E.Reed: variability in the amount of serologically detectable H-Y antigen.

Authors:  A Mayerová; U Müller; U Wiberg; U Wolf; M Fraccaro
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

Review 2.  HEL-12 virus: general considerations.

Authors:  S Panem
Journal:  Surv Immunol Res       Date:  1983

Review 3.  Autoimmune diseases: immunopathology and etiopathogenesis.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Am J Pathol       Date:  1982-09       Impact factor: 4.307

4.  Natural antibodies to the structural core protein (p24) of the human T-cell leukemia (lymphoma) retrovirus found in sera of leukemia patients in Japan.

Authors:  V S Kalyanaraman; M G Sarngadharan; Y Nakao; Y Ito; T Aoki; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

5.  Naturally occurring cytotoxic human antibodies recognize H-2-controlled murine lymphocyte antigens.

Authors:  P Iványi; T Leupers; P van Mourik
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

6.  Evidence in patients with systemic lupus erythematosus of the presence of antibodies against RNA-dependent DNA polymerase of baboon endogenous virus.

Authors:  T Okamoto; T Tamura; T Takano
Journal:  Clin Exp Immunol       Date:  1983-12       Impact factor: 4.330

Review 7.  Human leukemia viruses? RNA tumor viruses, human malignancies, and concepts of viral carcinogenesis.

Authors:  R Hehlmann; V Erfle
Journal:  Blut       Date:  1980-10

8.  Humans have antibodies capable of recognizing oncoviral glycoproteins: demonstration that these antibodies are formed in response to cellular modification of glycoproteins rather than as consequence of exposure to virus.

Authors:  M Barbacid; D Bolognesi; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

9.  Monoclonal antibodies against avian paramyxovirus-3: antigenic mapping and functional analysis of the haemagglutinin-neuraminidase protein and the characterization of nonspecific monoclonal antibodies.

Authors:  C L Anderson; P H Russell
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

Review 10.  RNA-tumorviruses, oncogenes, and their possible role in human carcinogenesis.

Authors:  R Hehlmann; H Schetters; G Kreeb; V Erfle; J Schmidt; A Luz
Journal:  Klin Wochenschr       Date:  1983-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.